Barclays
AVDL

Barclays’s Avadel Pharmaceuticals AVDL Stock Holding History

Barclays’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-11,000
Closed -$231K – 6820
2015
Q2 		$231K Buy
+11,000
New +$197K ﹤0.01% 4053

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's AVDL Position: Q1 2026 in Review

Barclays sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 148,858 shares — an estimated $3.21M sold.

Barclays first reported a position in AVDL in Q2 2013 and held it in 41 quarters. The position peaked at $5.15M in Q3 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Barclays reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Barclays sold 148,858 Avadel Pharmaceuticals shares in Q1 2026, an estimated $3.21M.
  • Barclays first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 41 quarters.
  • Barclays's Avadel Pharmaceuticals position peaked at $5.15M in Q3 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.